Renee Perdok

3.0k total citations · 1 hit paper
20 papers, 1.8k citations indexed

About

Renee Perdok is a scholar working on Rheumatology, Endocrinology, Diabetes and Metabolism and Immunology. According to data from OpenAlex, Renee Perdok has authored 20 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Rheumatology, 8 papers in Endocrinology, Diabetes and Metabolism and 6 papers in Immunology. Recurrent topics in Renee Perdok's work include Spondyloarthritis Studies and Treatments (8 papers), Hormonal and reproductive studies (7 papers) and Psoriasis: Treatment and Pathogenesis (6 papers). Renee Perdok is often cited by papers focused on Spondyloarthritis Studies and Treatments (8 papers), Hormonal and reproductive studies (7 papers) and Psoriasis: Treatment and Pathogenesis (6 papers). Renee Perdok collaborates with scholars based in United States, Canada and United Kingdom. Renee Perdok's co-authors include Philip J. Mease, Dafna D. Gladman, Christopher T. Ritchlin, John T. Sharp, P A Ory, Ernest Choy, Mark Weinberg, Eric H. Sasso, Eric Ruderman and Serge Steinfeld and has published in prestigious journals such as The Journal of Urology, Annals of the Rheumatic Diseases and European Urology.

In The Last Decade

Renee Perdok

18 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial

2005 702 citations Philip J. Mease, Dafna D. Gladman et al. Arthritis & Rheumatism profile →

Peers

Countries citing papers authored by Renee Perdok

Since Specialization

Citations

This map shows the geographic impact of Renee Perdok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renee Perdok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renee Perdok more than expected).

Fields of papers citing papers by Renee Perdok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renee Perdok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renee Perdok. The network helps show where Renee Perdok may publish in the future.

Co-authorship network of co-authors of Renee Perdok

This figure shows the co-authorship network connecting the top 25 collaborators of Renee Perdok. A scholar is included among the top collaborators of Renee Perdok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renee Perdok. Renee Perdok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials 2025 ·Thorax ·Judith J. Prochaska, (unknown), Renee Perdok, Brent A. Blumenstein, Cindy Jacobs	0
2	Randomized, double‐blind, placebo‐controlled study of interferon‐γ 1b in Friedreich Ataxia 2019 ·Annals of Clinical and Translational Neurology ·David R. Lynch, Lauren Hauser, (unknown), (unknown), Yi Dong, Shana E. McCormack, Kim Schadt, Susan Perlman, S. H. Subramony, Katherine D. Mathews, Alicia Brocht, Julie Ball, Renee Perdok, Amy Grahn, (unknown), Jeffrey W. Sherman, Jennifer Farmer	30
3	Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders 2018 ·Molecular Genetics and Metabolism ·Susan A. Berry, Jerry Vockley, Alexander A. Vinks, Min Dong, George A. Díaz, Shawn E. McCandless, Wendy E. Smith, Cary O. Harding, Roberto T. Zori, Can Fıçıcıoğlu, Uta Lichter‐Konecki, Renee Perdok, (unknown), Robert J. Holt, Nicola Longo	8
4	Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial 2011 ·Diabetes Obesity and Metabolism ·Ian D. Caterson, Nick Finer, Walmir Coutinho, Luc F. Van Gaal, Aldo P. Maggioni, Christian Torp‐Pedersen, Arya M. Sharma, Udo F. Legler, G Shepherd, Richard A. Rode, Renee Perdok, Cheryl Renz, W. P. T. James, (unknown)	108
5	Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT 2010 ·Arthritis Research & Therapy ·Dafna D. Gladman, Philip J. Mease, Ernest Choy, Christopher T. Ritchlin, Renee Perdok, Eric H. Sasso	71
6	Efficacy and safety of ABT-874, a monoclonal anti–interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial 2010 ·Journal of the American Academy of Dermatology ·Alexa B. Kimball, Kenneth B. Gordon, Richard G. Langley, Alan Menter, Renee Perdok, Joaquin Valdes	24
7	Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) 2008 ·Annals of the Rheumatic Diseases ·Philip J. Mease, P A Ory, John T. Sharp, Christopher T. Ritchlin, Filip Van den Bosch, (unknown), C. Birbara, G. T. D. Thomson, Renee Perdok, J Medich, Robert Wong, Dafna D. Gladman	214
8	Adalimumab for long‐term treatment of psoriatic arthritis: Forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trial 2007 ·Arthritis & Rheumatism ·Dafna D. Gladman, Philip J. Mease, Christopher T. Ritchlin, Ernest Choy, John T. Sharp, P A Ory, Renee Perdok, Eric H. Sasso	238
9	Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. 2007 ·PubMed ·Mark C. Genovese, Philip J. Mease, G. T. D. Thomson, Alan Kivitz, Renee Perdok, Mark Weinberg, J Medich, Eric H. Sasso, (unknown)	155
10	Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial 2006 ·Annals of the Rheumatic Diseases ·Dafna D. Gladman, Philip J. Mease, M. Cifaldi, Renee Perdok, Eric H. Sasso, J Medich	105
11	Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT 2005 ·Research Portal (King's College London) ·Philip J. Mease, Dafna D. Gladman, Christopher T. Ritchlin, Eric Ruderman, Ernest Choy, Serge Steinfeld, Renee Perdok, Eric H. Sasso, Mark Weinberg	2
12	Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial breakdown → 2005 ·Arthritis & Rheumatism ·Philip J. Mease, Dafna D. Gladman, Christopher T. Ritchlin, Eric Ruderman, Serge Steinfeld, Ernest Choy, John T. Sharp, P A Ory, Renee Perdok, Mark Weinberg	702
13	Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study 2004 ·Research Portal (King's College London) ·Philip J. Mease, Dafna D. Gladman, Christopher T. Ritchlin, Eric Ruderman, (unknown), Ernest Choy, Renee Perdok, (unknown)	19
14	Cross-Study Review of the Clinical Efficacy of Apomorphine SL 2 and 3 mg: 2002 ·European Urology Supplements ·Christian G. Stief, Robert J. Padley, Renee Perdok, Darryl J. Sleep	13
15	Uprima (apomorphine SL) 2 and 3 MG is well-tolerated and effective in men with Erectile Dysfunction (ED) concurrently taking antidepressant medication 2002 ·European Urology Supplements ·Jeremy P.W. Heaton, Darryl J. Sleep, Renee Perdok, (unknown)	1
16	Safety and Tolerability of Apomorphine SL in Men with Cardiovascular Disorders 2002 ·European Urology Supplements ·Michael A. Adams, Renee Perdok, Robert J. Padley, Darryl J. Sleep	10
17	Safety of uprima (apomorphine SL) 2 and 3 MG in men with Erectile Dysfunction (ED) concurrently taking nitrate medication 2002 ·European Urology Supplements ·Jeremy P.W. Heaton, Darryl J. Sleep, Renee Perdok, (unknown)	0
18	Adverse Events and Patient Tolerability of Apomorphine SL 2 and 3 mg: A Cross-Study Analysis of Phase II and III Studies 2002 ·European Urology Supplements ·David Ralph, Darryl J. Sleep, Renee Perdok, Robert J. Padley	9
19	Double–Blind, Crossover Comparison of 3 mg Apomorphine SL with Placebo and with 4 mg Apomorphine SL in Male Erectile Dysfunction 2001 ·European Urology ·Eugene Dula, Stan Bukofzer, Renee Perdok, Michael George	104
20	EFFICACY AND SAFETY OF APOMORPHINE SL VS PLACEBO FOR MALE ERECTILE DYSFUNCTION (MED) 1999 ·The Journal of Urology ·Harin Padma-Nathan, Stephen M. Auerbach, R. M. Lewis, (unknown), Renee Perdok	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact